Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975997 · ClinicalTrials.gov registry record · Phase 3
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 study of Multiple Myeloma, sponsored by Celgene.
- Active
- Registry status
- Phase 3
- Development phase
- 864
- Enrollment target
- 20
- Study locations
NCT04975997: Active Phase 3 study of Multiple Myeloma, sponsored by Celgene.
NCT04975997 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by Celgene. The registered enrollment target is 864 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (59% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04975997, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Celgene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 864 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Primary Outcome
To compare the efficacy of iberdomide (also known as BMS-986382), daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) in terms of progression free survival (PFS).
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Iberdomide
- DRUG Bortezomib
Study Locations (20)
Florida
- Local Institution - 029 - Fort Myers
- Local Institution - 693 - Ocala
- Local Institution - 028 - St. Petersburg
- Local Institution - 045 - Tamarac
- Local Institution - 034 - West Palm Beach
- Local Institution - 685 - Weston
California
- Local Institution - 641 - Cerritos
- Local Institution - 681 - Fountain Valley
- Local Institution - 047 - Los Angeles
- Local Institution - 684 - Newport
Louisiana
- Local Institution - 041 - Alexandria
- Local Institution - 682 - Baton Rouge
- Local Institution - 027 - Baton Rouge
Arkansas
- Local Institution - 035 - Hot Springs
Connecticut
- Local Institution - 033 - New Haven
Georgia
- Local Institution - 018 - Atlanta
Illinois
- Local Institution - 640 - Elk Grove Village
Indiana
- Local Institution - 697 - Dyer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 864 participants |
| Start Date | 2022-06-23 |
| Est. Completion | 2032-06-25 |
| Phase | Phase 3 |
What the registry record for NCT04975997 still lists
NCT04975997 is an interventional study that assigns participants to a tested intervention. The registered 864 participants enrollment target is mid-sized for trials with a published cap, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (59% higher).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT04975997 names 20 study sites across 10 states, led by Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT04975997 about?
NCT04975997 is a clinical study titled "Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)". This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple ...
What is the current status of trial NCT04975997?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 864 participants. The study started on 2022-06-23. Estimated completion is 2032-06-25.
What conditions does trial NCT04975997 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04975997?
The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Iberdomide (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT04975997?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04975997 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04975997's enrollment target sits among peer trials
864 26th of 438 higher than 413 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06256588 · 864 participants · Phase 3
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- NCT06527794 · 864 participants · NA
Remote Hypertension Management for Black Patients
- NCT05369052 · 865 participants · Phase 3
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
- NCT05914116 · 862 participants · Phase 1
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI